UNION therapeutics announces enrollment of first patient in the IASOS Phase 2b study of oral orismilast in psoriasis patients
IASOS is a Phase 2b dose-ranging study of oral orismilast in psoriasis patients with the purpose of identifying the appropriate dose-regimen for Phase 3 studies Orismilast is a next generation […]
UNION therapeutics receives FDA Fast Track designation for oral orismilast for the treatment of moderate to severe atopic dermatitis
FDA’s Fast Track designation for oral orismilast underscores the urgent need for new treatment option with potential to fulfil the unmet medical needs for people affected by atopic dermatitis (AD) […]
UNION therapeutics announces enrollment of first patient in the OSIRIS Phase 2a study of oral orismilast for the treatment of mild to severe hidradenitis suppurativa
OSIRIS is an investigator-led, proof-of-concept Phase 2 study of orismilast for the treatment of mild to severe hidradenitis suppurativa (HS) HS is a scarring inflammatory skin disease with significant unmet […]
UNION therapeutics and Innovent Biologics enter into strategic collaboration and license agreement for orismilast, a next-generation PDE4 inhibitor for inflammatory dermatology conditions
Orismilast is a potential best-in-class PDE4 inhibitor in Phase 2 clinical development for the treatment of atopic dermatitis, psoriasis, and hidradenitis suppurativa Innovent will be granted exclusive rights to research, […]
UNION therapeutics welcomes life science leaders Gitte Aabo and Arthur Higgins as new members of the Board of Directors
Hellerup, Denmark, 12 July 2021 – UNION therapeutics A/S, a privately-held, multi-asset, clinical stage pharmaceutical company focused on immunology and infectious diseases, today announced that Gitte Aabo, CEO of GN […]
UNION therapeutics further strengthens management team with medical and business development profiles
Dr. Per Cantor, MD, DMSci, appointed as new Chief Medical Officer Mr. Eckhard Niemeier appointed as Chief Business Officer Mr. Mads Jellingsø promoted to Chief Commercial Officer Hellerup, Denmark, 31 […]
UNION therapeutics’ COVID-19 candidates found to be well tolerated in Phase 1 Lancet publication
The Lancet Regional Health – Europe has published the results of UNION therapeutics’ phase 1 study of inhaled and intranasal niclosamide products (UNI91103 and UNI91104) The study endpoints were to […]
The PROTECT-V trial investigating UNIONs COVID-19 candidate receives Urgent Public Health Prioritization from the UK government
Hellerup, Denmark, March 29, 2021 – UNION therapeutics A/S (UNION) today announced that the National Institute for Health Research (NIHR) in the UK has granted Urgent Public Health (UPH) prioritization to […]
The PROTECT-V trial investigating UNIONs COVID-19 candidate receives Urgent Public Health Prioritization from the UK government
Hellerup, Denmark, March 29, 2021 – UNION therapeutics A/S (UNION) today announced that the National Institute for Health Research (NIHR) in the UK has granted Urgent Public Health (UPH) prioritization to […]
UNION’s nasal spray for COVID-19 enters a 1,500 high-risk patient study
UNI91103 is a nasal spray delivering niclosamide – a potent inhibitor of SARS-CoV-2 with in-vitro potency >40x higher than remdesivir – to the nasal cavity UNI91103 has been selected as […]
